Llwytho...
ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies
ENaC inhibition with BI 1265162 is a promising strategy to optimise outcomes in patients with CF either eligible, or ineligible, for CFTR modulator therapy. Phase II clinical trials of BI 1265162 must now show this translates into clinical benefit. https://bit.ly/2OQ1IUI
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Eur Respir J |
|---|---|
| Prif Awdur: | |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
European Respiratory Society
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7758539/ https://ncbi.nlm.nih.gov/pubmed/32732328 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/13993003.00946-2020 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|